Literature DB >> 33523229

PD-L1 in Breast Cancer: The Road to the Perfect BiomarkerIs Fraught With Uncertainty.

Bora Lim1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33523229      PMCID： PMC8328981          DOI： 10.1093/jnci/djab005

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  14 in total

1.  Immune cell repertoires in breast cancer patients after adjuvant chemotherapy.

Authors:  Claire E Gustafson; Rohit Jadhav; Wenqiang Cao; Qian Qi; Mark Pegram; Lu Tian; Cornelia M Weyand; Jorg J Goronzy
Journal:  JCI Insight       Date:  2020-02-27

2.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

3.  Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

Authors:  Javier Cortes; David W Cescon; Hope S Rugo; Zbigniew Nowecki; Seock-Ah Im; Mastura Md Yusof; Carlos Gallardo; Oleg Lipatov; Carlos H Barrios; Esther Holgado; Hiroji Iwata; Norikazu Masuda; Marco Torregroza Otero; Erhan Gokmen; Sherene Loi; Zifang Guo; Jing Zhao; Gursel Aktan; Vassiliki Karantza; Peter Schmid
Journal:  Lancet       Date:  2020-12-05       Impact factor: 79.321

4.  Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

Authors:  Rita Nanda; Laura Q M Chow; E Claire Dees; Raanan Berger; Shilpa Gupta; Ravit Geva; Lajos Pusztai; Kumudu Pathiraja; Gursel Aktan; Jonathan D Cheng; Vassiliki Karantza; Laurence Buisseret
Journal:  J Clin Oncol       Date:  2016-05-02       Impact factor: 44.544

5.  Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.

Authors:  Elizabeth A Mittendorf; Hong Zhang; Carlos H Barrios; Shigehira Saji; Kyung Hae Jung; Roberto Hegg; Andreas Koehler; Joohyuk Sohn; Hiroji Iwata; Melinda L Telli; Cristiano Ferrario; Kevin Punie; Frédérique Penault-Llorca; Shilpen Patel; Anh Nguyen Duc; Mario Liste-Hermoso; Vidya Maiya; Luciana Molinero; Stephen Y Chui; Nadia Harbeck
Journal:  Lancet       Date:  2020-09-20       Impact factor: 79.321

6.  Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.

Authors:  Robert M Samstein; Chirag Krishna; Xiaoxiao Ma; Xin Pei; Ken-Wing Lee; Vladimir Makarov; Fengshen Kuo; Jonathan Chung; Raghvendra M Srivastava; Tanaya A Purohit; Douglas R Hoen; Rajarsi Mandal; Jeremy Setton; Wei Wu; Rachna Shah; Besnik Qeriqi; Qing Chang; Sviatoslav Kendall; Lior Braunstein; Britta Weigelt; Pedro Blecua Carrillo Albornoz; Luc G T Morris; Diana L Mandelker; Jorge S Reis-Filho; Elisa de Stanchina; Simon N Powell; Timothy A Chan; Nadeem Riaz
Journal:  Nat Cancer       Date:  2020-11-16

7.  Pembrolizumab for Early Triple-Negative Breast Cancer.

Authors:  Peter Schmid; Javier Cortes; Lajos Pusztai; Heather McArthur; Sherko Kümmel; Jonas Bergh; Carsten Denkert; Yeon Hee Park; Rina Hui; Nadia Harbeck; Masato Takahashi; Theodoros Foukakis; Peter A Fasching; Fatima Cardoso; Michael Untch; Liyi Jia; Vassiliki Karantza; Jing Zhao; Gursel Aktan; Rebecca Dent; Joyce O'Shaughnessy
Journal:  N Engl J Med       Date:  2020-02-27       Impact factor: 176.079

8.  Quantitative assessment of PD-L1 as an analyte in immunohistochemistry diagnostic assays using a standardized cell line tissue microarray.

Authors:  Sandra Martinez-Morilla; John McGuire; Patricia Gaule; Lauren Moore; Balazs Acs; Delphine Cougot; Allen M Gown; Hadi Yaziji; Wei-Lien Wang; Richard W Cartun; Jason L Hornick; Lynette M Sholl; Jingxin Qiu; Mari Mino-Kenudson; Eunhee S Yi; Mary Beth Beasley; Daniel T Merrick; Abiy B Ambaye; Zhong J Zhang; Jill Walker; David L Rimm
Journal:  Lab Invest       Date:  2019-08-13       Impact factor: 5.662

9.  Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers.

Authors:  Mariya Rozenblit; Richard Huang; Natalie Danziger; Priti Hegde; Brian Alexander; Shakti Ramkissoon; Kim Blenman; Jeffrey S Ross; David L Rimm; Lajos Pusztai
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 13.751

10.  Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.

Authors:  Leisha A Emens; Luciana Molinero; Sherene Loi; Hope S Rugo; Andreas Schneeweiss; Véronique Diéras; Hiroji Iwata; Carlos H Barrios; Marina Nechaeva; Anh Nguyen-Duc; Stephen Y Chui; Amreen Husain; Eric P Winer; Sylvia Adams; Peter Schmid
Journal:  J Natl Cancer Inst       Date:  2021-08-02       Impact factor: 13.506
View more
  1 in total

1.  Multiplexed immunofluorescence identifies high stromal CD68+PD-L1+ macrophages as a predictor of improved survival in triple negative breast cancer.

Authors:  James Wang; Lois Browne; Iveta Slapetova; Fei Shang; Kirsty Lee; Jodi Lynch; Julia Beretov; Renee Whan; Peter H Graham; Ewan K A Millar
Journal:  Sci Rep       Date:  2021-11-03       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.